Zuckerman Investment Group LLC Lowers Stake in Icon Plc $ICLR

Zuckerman Investment Group LLC lessened its stake in shares of Icon Plc (NASDAQ:ICLR) by 4.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 151,746 shares of the medical research company’s stock after selling 6,456 shares during the quarter. Icon makes up about 2.5% of Zuckerman Investment Group LLC’s portfolio, making the stock its 12th biggest position. Zuckerman Investment Group LLC’s holdings in Icon were worth $26,556,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in ICLR. Private Trust Co. NA raised its position in shares of Icon by 200.0% in the 3rd quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock worth $25,000 after acquiring an additional 94 shares in the last quarter. Ameriflex Group Inc. bought a new stake in Icon during the third quarter valued at about $33,000. Wilmington Savings Fund Society FSB grew its stake in Icon by 153.4% in the third quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 201 shares during the last quarter. Pilgrim Partners Asia Pte Ltd bought a new position in Icon in the third quarter worth about $63,000. Finally, Johnson Financial Group Inc. purchased a new stake in shares of Icon during the third quarter valued at about $71,000. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

Icon Stock Performance

ICLR opened at $98.33 on Friday. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon Plc has a 12-month low of $66.57 and a 12-month high of $211.00. The firm has a 50 day moving average of $144.09 and a two-hundred day moving average of $165.50. The firm has a market capitalization of $7.94 billion, a PE ratio of 13.31, a P/E/G ratio of 2.50 and a beta of 1.35.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ICLR shares. Rothschild & Co Redburn set a $100.00 price target on shares of Icon and gave the company a “neutral” rating in a report on Tuesday, February 17th. Robert W. Baird set a $119.00 target price on shares of Icon in a research report on Friday, February 13th. Bank of America restated an “underperform” rating and issued a $75.00 target price on shares of Icon in a research note on Thursday, February 12th. Leerink Partners reaffirmed a “market perform” rating and set a $105.00 price target on shares of Icon in a research report on Thursday, February 12th. Finally, Mizuho set a $216.00 price objective on Icon in a report on Friday, January 9th. Six analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $146.80.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.